Gilead CFO sells 3,000 shares under trading plan
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Gilead Sciences Chief Financial Officer Andrew D. Dickinson carried out an open-market sale of 3,000 shares of common stock on July 15, 2026 at an average price of $129.9256 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, and he continues to hold 168,646 shares directly.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 3,000 | $129.9256 | $390K |
Footnotes (2)
- F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
- F2. Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
open-market sale financial
non-derivative financial
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Gilead Sciences (GILD) report for its CFO?
Was the Gilead Sciences (GILD) CFO sale made under a Rule 10b5-1 plan?
What type of security was involved in the GILD CFO’s Form 4 transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.